<![CDATA[Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera]]>

RegulatorypositiverusfertidePositive

AI Analysis

Summary

Rusfertide has received a Category 1 recommendation from the NCCN Guidelines for treatment of both low- and high-risk polycythemia vera, representing clinical validation of the therapy.

Outcome Details

Category 1 NCCN recommendation for rusfertide in low- and high-risk polycythemia vera

Importance:7/10

Sentiment:

0.75

NCCN guidelinepolycythemia veramyeloproliferative neoplasmregulatory endorsement

Related Companies

$VERX $NHPAP

Read the original article

Published by Cancer Network on September 22, 2026 1:00 PM

Read Original